Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Sees Large Decline in Short Interest

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) was the target of a large decline in short interest in the month of June. As of June 30th, there was short interest totaling 12,043 shares, a decline of 57.9% from the June 15th total of 28,598 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average trading volume of 43,196 shares, the short-interest ratio is currently 0.3 days.

Institutional Trading of Oaktree Acquisition Corp. III Life Sciences

Hedge funds have recently made changes to their positions in the business. Empyrean Capital Partners LP boosted its stake in shares of Oaktree Acquisition Corp. III Life Sciences by 20.0% in the fourth quarter. Empyrean Capital Partners LP now owns 900,000 shares of the company’s stock valued at $9,522,000 after purchasing an additional 150,000 shares during the period. Lighthouse Investment Partners LLC lifted its holdings in Oaktree Acquisition Corp. III Life Sciences by 88.9% during the 2nd quarter. Lighthouse Investment Partners LLC now owns 850,000 shares of the company’s stock worth $8,882,000 after buying an additional 400,000 shares in the last quarter. Sculptor Capital LP lifted its holdings in Oaktree Acquisition Corp. III Life Sciences by 6.1% during the 4th quarter. Sculptor Capital LP now owns 530,537 shares of the company’s stock worth $5,613,000 after buying an additional 30,537 shares in the last quarter. Goldman Sachs Group Inc. purchased a new position in Oaktree Acquisition Corp. III Life Sciences in the 1st quarter valued at approximately $5,417,000. Finally, Moore Capital Management LP purchased a new position in Oaktree Acquisition Corp. III Life Sciences in the 2nd quarter valued at approximately $5,502,000.

Oaktree Acquisition Corp. III Life Sciences Price Performance

OACC traded up $0.03 during mid-day trading on Tuesday, hitting $10.72. 3,040 shares of the stock were exchanged, compared to its average volume of 38,198. The firm’s fifty day moving average is $10.69 and its two-hundred day moving average is $10.66. Oaktree Acquisition Corp. III Life Sciences has a 1-year low of $10.30 and a 1-year high of $10.74.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Oaktree Acquisition Corp. III Life Sciences in a research report on Tuesday, June 30th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Oaktree Acquisition Corp. III Life Sciences has a consensus rating of “Sell”.

Oaktree Acquisition Corp. III Life Sciences Company Profile

Oaktree Acquisition Corp. III Life Sciences (NASDAQ: OACC) is a special purpose acquisition company (“SPAC”) formed to pursue merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combinations with one or more businesses in the life sciences sector. Incorporated as a Cayman Islands exempted company, OACC is sponsored by Oaktree Capital Management, a global alternative investment firm with a longstanding track record in credit strategies and private equity.